FDA’s medical review departments remain largely untouched (for now) by Musk-led cuts
Based on the search results, here are the key points about FDA medical review departments and recent cuts:
The FDA's units responsible for reviewing new medical products have remained largely untouched by recent cuts implemented by Elon Musk's Department of Government Efficiency (DOGE).
Reports indicate that while thousands of government workers have been laid off across health agencies, the FDA's main drug review offices were "relatively spared" from cuts.
However, cuts did affect some FDA offices, including:
At least 230 employees in the FDA office regulating medical devices were cut
Some staff who review medical device products were laid off
Officials working on artificial intelligence and technology at FDA were cut
There were cuts in the FDA office that conducts inspections and criminal investigations
Experts warn that even limited cuts could slow the FDA's ability to evaluate and approve new drugs and devices.
The full impact remains uncertain, as the cuts were described as chaotic and haphazard by some insiders.
There are concerns that cuts to probationary employees and new hires could impede FDA's efforts to expand in priority areas like AI.
The situation is still evolving, with the possibility of further cuts or changes in the future.